Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Levomilnacipran SR in Major Depressive Disorder
NCT01034267Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Dec 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levomilnacipran in major depressive disorder (MDD), sponsored by Forest Laboratories. Started Dec 2009; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01034267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01034267.